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Abstract
 .  .Iron Fe chelators of the pyridoxal isonicotinoyl hydrazone PIH class may be useful agents to treat Fe overload disease
and also cancer. These ligands possess high activity at mobilizing 59 Fe from neoplastic cells, and the present study has been
designed to examine whether their marked activity may be related to an energy-dependent transport process across the cell
59  .membrane. Initial experiments examined the release of Fe from SK-N-MC neuroblastoma NB cells prelabelled for 3 h at
59  .378C with Fe-transferrin 1.25 mM and then reincubated in the presence and absence of the chelators for 3 h at 48C or
378C. Prelabelled cells released 4–5% of total cellular 59 Fe when reincubated in minimum essential medium at 48C or 378C.
 .  .When the chelators desferrioxamine DFO; 0.1 mM or PIH 0.1 mM were reincubated with labelled cells at 48C, they
mobilized only 4–5% of cellular 59 Fe, whereas as 378C, these ligands mobilized 21% and 48% of cell 59 Fe, respectively.
 .The lipophilic PIH analogue, 311 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone; 0.1 mM , which exhibits high
anti-proliferative activity, released 10% and 53% of cellular 59 Fe when reincubated with prelabelled cells at 48C and 378C,
respectively. Almost identical results were obtained using the SK-Mel-28 melanoma cell line. These data suggest that
perhaps temperature-dependent mechanisms are essential for 59 Fe mobilization from these cells. Interestingly, the metabolic
inhibitors, 2,4-dinitrophenol, oligomycin, rotenone, and sodium azide, markedly decreased 59 Fe mobilization mediated by
PIH, but had either no effect or much less effect on 59 Fe release by 311. Considering that an ATP-dependent process was
involved in 59 Fe release by PIH, further studies examined 4 widely used inhibitors of the multi-drug efflux pump
 .  .  .  .P-glycoprotein P-gp . All of these inhibitors, namely, verapamil Ver , cyclosporin A CsA , reserpine Res and quinine
 . 59 59Qui , decreased Fe mobilization by PIH but had little or no effect on Fe release mediated by analogue 311. Further,
both CsA and Ver increased the proportion of ethanol-soluble 59 Fe within cells in the presence of PIH, suggesting inhibited
transport of the 59 Fe complex from the cell. However, when PIH-mediated 59 Fe release was compared between a well
 R .characterized Chinese hamster ovary cell line CH B30 expressing high levels of P-gp and the relevant control cell line
 . 59AuxB1 , no appreciable difference in the kinetics of Fe release were found. In contrast, it was intriguing that the
R 59  . CH B30 cells released more Fe into control medium i.e., without PIH than the AuxB1 control line 16.7% compared to
.5.9%, respectively . In summary, the results suggest that a temperature- and energy-dependent process was involved in the
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efflux of the PIH- 59 Fe complex from the cells. In contrast, 59 Fe release mediated by 311 was temperature-dependent but not
energy-dependent, and could occur by simple diffusion or passive transport. Further studies investigating the membrane
transport of Fe chelators may be useful in designing regimes that potentiate their anti-neoplastic effects.q 1997 Elsevier
Science B.V. All rights reserved.
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1. Introduction
 .The development of iron Fe chelators for clinical
use has traditionally been focussed on their ability to
remove Fe from patients suffering Fe overload dis-
eases such as thalassemia. However, it has become
clear that Fe chelators may also be useful for treating
w xa number of disease states 1 . In fact, these com-
w xpounds are effective at treating malaria 1,2 , for
w xpreventing free radical-mediated tissue damage 3 ,
w xand for inhibiting tumor cell growth 4 . For example,
 .the tris-hydroxamate Fe III chelator, desferrioxamine
 .DFO , is widely used for the treatment of Fe over-
load, and more recently has been shown to be effec-
tive at inhibiting the proliferation of neuroblastoma
 . w x w x w xNB cells 5 , hepatoma cells 6 , leukemia cells 7
w xand melanoma cells 8 . Apart from DFO, a range of
Fe chelators have also been investigated for their
anti-proliferative effects in a wide spectrum of cell
w xtypes 9,10 .
The tridentate Fe chelator, pyridoxal isonicotinoyl
 .hydrazone PIH , is highly effective at mobilizing
59Fe from both normal and neoplastic cells, being far
w xmore efficient than DFO 11–13 . Moreover, a clini-
cal trial with PIH showed no evidence of toxicity and
w xresulted in significant Fe excretion 14 . Considering
the efficacy of PIH, a range of PIH analogues were
synthesized and several showed high activity, these
compounds having potential as agents to treat Fe
w xoverload 12,15 . Since NB cells appear to be particu-
w xlarly sensitive to DFO 5 , we have recently examined
the use of the PIH analogues as effective anti-pro-
w xliferative agents 16–18 . While PIH displayed low
anti-proliferative activity, some of its analogues, par-
ticularly the lipophilic hydrazones derived from 2-hy-
droxy-1-naphthylaldehyde, showed high efficacy at
inhibiting the growth of NB cells and other neoplastic
w xcells in vitro 17,18 . These compounds were particu-
larly active at mobilizing 59Fe from prelabelled cells,
being far more efficient than DFO. The high rate of
59 w xFe efflux in the presence of the chelators 16–18
suggested that perhaps these ligands were being ac-
tively extruded from the cell. Previous studies by
w xHuang and Ponka 19 demonstrated that an energy-
dependent process was involved in the release of the
PIH-59Fe complex from 59Fe-loaded erythroid cells.
However, these studies were performed using rabbit
reticulocytes that had been treated with the heme
w xsynthesis inhibitor succinylacetone 19 . Treatment of
reticulocytes with this latter agent results in an accu-
59 w xmulation of Fe in the mitochondrion 20 , a chelat-
able pool of 59Fe that is not present under physio-
w xlogical conditions 21 . Hence, the relevance of this
work to human neoplastic cells is unclear. In addi-
tion, Huang and Ponka only examined the efflux of
w xPIH 19 , the mechanism of release of the effective
anti-tumor agents derived from 2-hydroxy-1-naph-
w xthylaldehyde 17,18 were not assessed.
In the present study, human neoplastic cells have
been used to examine the mechanism of PIH-media-
ted 59Fe release compared to its lipophilic analogue,
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydra-
 .zone 311 , a chelator that is an active anti-prolifera-
w xtive agent 17,18 . These experiments were under-
taken in an attempt to understand the membrane
transport of Fe chelators in view of designing regimes
that enhance their anti-tumor effects.
2. Materials and methods
2.1. Materials
 .Iron-59 as ferric chloride in 0.1 M HCl was
purchased from Dupont, NEN products, Boston, MA.
 .Human transferrin Tf was purchased from
Boehringer-Mannheim, Mannheim, Germany. Eagle’s
 .modified minimum essential medium MEM , a-
MEM containing ribonucleosides and deoxyribonu-
 .cleosides, Hanks’ balanced salt solution BSS and
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penicillin-streptomycin were obtained from Gibco
 .Laboratories, Canada. Fungizone amphotericin B
was obtained from Squibb Pharmaceuticals, Montreal,´
 .Canada. Fetal calf serum FCS was from Wisent, St.
Bruno, Quebec, Canada. Colchicine, 2,4-dinitro-´
phenol, oligomycin, quinine, reserpine, rotenone,
sodium azide, verapamil, and vinblastine, were ob-
 .tained from Sigma Chemical Co. St. Louis, MO .
 .Cyclosporin A Sandimmune was from Sandoz, Dor-
val, Quebec, Canada. Desferrioxamine desferrioxa-´
.mine mesylate was obtained from Ciba-Geigy Phar-
maceutical, Summit, NJ. All other chemicals were of
analytical reagent quality.
2.2. Preparation of the chelators
Chelators were synthesized by Schiff base conden-
sation between 3 aromatic aldehydes pyridoxal, ‘100
series’; salicylaldehyde, ‘200 series’; 2-hydroxy-1-
.naphthylaldehyde, ‘300 series’ and a series of acid
hydrazides using standard procedures as described
w xpreviously 15,17 . In the present study we have
primarily examined the activity of PIH compared to
analogue 311, although in some experiments, the
effect of DFO, 206 salicylaldehyde p-t-butylbenzoyl
. benzoyl hydrazone , 309 2-hydroxy-1-naph-
.thylaldehyde m-fluorobenzoyl hydrazone and 315
2-hydroxy-1-naphthylaldehyde 2-thiophenecarboxyl
.hydrazone were also examined. The PIH analogues
have previously been characterized with respect to
their molecular weights, melting points and infrared
w xspectra 22 . The ligands were dissolved in dimethyl
 .sulphoxide DMSO as 10 mM stock solutions imme-
diately prior to an experiment and then diluted so that
the final concentration of DMSO was equal to 0.1%
 .vrv . After dilution, the solutions were mixed vigor-
ously to ensure total solubilization. In all experiments
with chelators dissolved in MEM or PBS, 1% FCS
was added to prevent the compounds from coming
out of solution.
In the initial stages of this investigation enquiries
were made concerning the 14C-labelling of PIH and
its analogues, as this would provide an ideal method
for examining their mechanism of uptake and release.
However, no 14C-labelled precursors of the chelators
were commercially available. This would necessitate
custom synthesis of the 14C-labeled ligands which
was very expensive, and this prevented their use in
the present study.
2.3. Protein purification and labelling
Human apotransferrin was prepared and labelled
59 59 59 .with Fe to produce Fe -transferrin Fe-Tf , as2
w xdescribed by Richardson and Baker 23 .
2.4. Cell culture
The human NB cell line, SK-N-MC, and the hu-
man melanoma cell line, SK-Mel-28, were obtained
from the American Type Culture Collection Rock-
.ville, MD , and were grown in MEM containing 10%
 .FCS, 1% vrv non-essential amino acids, 100
mgrml of streptomycin, 100 Urml penicillin and
0.28 mgrml of fungizone. Cells were subcultured
and used for experiments as described in previous
w xwork 23 . The SK-N-MC and SK-Mel-28 melanoma
cell lines were chosen as the Fe metabolism of these
cells were characterized in prior investigations
w x16,23 , and both lines were shown to be sensitive to
the growth inhibitory effects of the PIH analogues
w x17,18 . In all studies confluent monolayers of cells
were used without cellular overgrowth.
The well characterized CHRB30 Chinese hamster
 .ovary cells with high P-glycoprotein P-gp levels
and its parental control, AuxB1, were kindly supplied
by Dr. Victor Ling, British Columbia Cancer Agency,
Vancouver, Canada. The CHRB30 CHO cell line was
selected by continuous culture in increasing concen-
trations of colchicine from the CHO cell line CHRC5
w x R24 , and the CH C5 line was clonally selected,
w xstepwise, from Aux B1 25 . The Aux B1 and
CHRB30 CHO cell lines were grown in a-MEM
containing ribonucleosides and deoxyribonucleosides
supplemented with 10% FCS. Twenty-four hours af-
ter passaging, 30 mgrml of colchicine was added to
the medium of the CHRB30 cells and the cultures
then allowed to grow to near confluence Kelly Fox
.and Victor Ling, personal communication . All exper-
iments with these cell lines was perfomed using
cultures close to confluence. The CHRB30 cells have
been shown to express very high levels of P-gp and
to display multi-drug resistance, while AuxB1 is
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drug-sensitive and has only trace amounts of P-gp
w x24,26 .
2.5. The effect of temperature and inhibitors on
chelator-mediated iron release
The effect of temperature on chelator-mediated
59Fe release was studied using standard procedures
w x15–17 . Briefly, cells were prelabelled for 3 h at
59  .378C with MEM containing Fe-Tf 1.25 mM . Af-
ter this incubation, the cells were placed on a tray of
ice and washed 4 times with ice-cold BSS and then
reincubated for up to 3 h at either 48C or 378C with
medium alone or medium containing the chelators
 .0.1 mM . For reincubation times up to 3 h at 48C or
378C, cells remained viable as judged by cellular
morphology, adherence to the culture substratum and
the exclusion of trypan blue. At the end of the
reincubation period, the overlying medium was re-
moved and placed in counting tubes to estimate the
release of 59Fe. The cells were then scraped from the
plates in 1 ml of BSS using a teflon spatula and put
into counting tubes to estimate cellular 59Fe. Radioac-
tivity was measured using a LKB 1282 Com-
pugamma counter. As an estimate of cell density the
Fig. 1. The effect of incubation temperature on chelator-mediated
59Fe release from prelabelled SK-N-MC neuroblastoma cells.
59 Cells were prelabelled for 3 h at 378C with Fe-transferrin 1.25
.mM , washed, and then reincubated in the absence or presence of
 .the chelators 0.1 mM for 3 h at 48C or 378C. Results are
presented as the Mean"S.D. of three replicates in a typical
experiment of two experiments performed.
Fig. 2. The effect of incubation temperature on the kinetics of
59Fe release from SK-N-MC neuroblastoma cells in the presence
or absence of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydra-
 . 59 zone 311 . Cells were prelabelled with Fe-transferrin 1.25
.mM for 3 h at 378C, washed, and then reincubated for up to 3 h
at 48C or 378C with control medium alone or medium containing
 .chelator 311 0.1 mM . Exactly comparable results were obtained
for PIH. Results are means of duplicate determinations in a
typical experiment of two experiments performed. Variation be-
tween replicates was less than 5%.
cell pellet was resuspended in 1 ml of BSS, sonicated
for 15 s, and an aliquote used to determine protein
 .concentration by the bicinchoninic acid BCA
 .method Pierce Chemical, Rockford, IL, 61105, USA
w x23 . Results are expressed as either the percentage of
cellular 59Fe released or as nmoles Fe per gram of
 .protein gPR .
2.6. The effect of inhibitors on chelator-mediated iron
release
Standard methods were implemented to assess the
effects of inhibitors on 59Fe release by the chelators
w x19 . Briefly, cells were prelabelled using a 3 h
59  .incubation at 378C with Fe-Tf 1.25 mM in MEM,
then placed on a tray of ice and washed 4 times with
ice-cold BSS. The cells were then preincubated with
the inhibitor for 30 min or 60 min at 378C, this
medium removed, and replaced with medium contain-
ing either the inhibitor alone or the inhibitor and the
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Fig. 3. A: the effect of a range of inhibitors on PIH or analogue 311-mediated 59Fe release from prelabelled SK-N-MC neuroblastoma
59  .cells. Cells were labelled with Fe-transferrin 1.25 mM for 3 h at 378C, washed, and then preincubated for 30 min at 378C with the
inhibitor in PBS. This solution was removed and replaced with PBS containing the inhibitor alone or the inhibitor and the chelator 50
. 59mM which was incubated with the cells for 60 min at 378C. B: the effect of the inhibitors on the total amount of Fe in the cells.
 .  . Incubation conditions were the same as described for A . C: the effect of 2,4-dinitrophenol DNP; 200 mM or vinblastine VBL; 50
. 59  .  .  .mM on Fe release by DFO 100 mM , PIH 50 mM , or the PIH analogues 206, 309, 311 and 315 50 mM . Incubation conditions
 .were the same as those described for A . Results are means of duplicate determinations from a typical experiment of 3 experiments
performed. Variation between replicates was generally less than 5%.
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chelator. Results were compared to when prelabelled
cells were preincubated with medium alone for 30
min or 60 min and then exposed to either medium
alone or medium containing the chelator. At the end
of the reincubation, the overlying medium was re-
moved and placed into counting tubes to estimate
59Fe release. The cells were then scraped from the
plates in 1 ml of BSS and put into counting tubes to
estimate cellular 59Fe.
For experiments using metabolic inhibitors sodium
.azide, 2,4-dinitrophenol, rotenone, oligomycin and
 .microtubule inhibitors vinblastine and colchicine ,
 .these compounds were prepared in PBS pH 7.4 and
preincubated with cells for 30 min at 378C. This
solution was then removed and replaced with
PBSr1% FCS containing either PIH or 311 in the
presence of the inhibitors. In these studies, PBS was
used instead of MEM, as it does not contain glucose,
and hence, aids the metabolic depletion induced by
adding sodium azide, 2,4-dinitrophenol, rotenone and
oligomycin. As described above, 1% FCS was added
with the chelators to prevent them coming out of
solution in PBS. In experiments with inhibitors shown
to prevent P-glycoprotein transport activity, namely,
 .  .  .cyclosporin A CsA , quinine Qui , reserpine Res
 .and verapamil Ver , these compounds were prepared
in MEM.
2.7. Estimation of chelator-bound 59Fe in cells using
ethanol precipitation
The amount of chelator-bound 59Fe within cells
was estimated by standard techniques using ethanol
w xprecipitation 19 . Briefly, cells were lyzed by scrap-
ing them from the petri dishes in 0.5 ml of ice-cold
doubly distilled water and the cell suspension trans-
ferred to Eppendorf tubes at 48C. Ice-cold 95%
 .ethanol 1.0 ml was then added with vigorous mix-
ing and the tubes left on ice for 30 min. After this
incubation, the tubes were placed in an IEC Micro-
 .Max microcentrifuge IEC, Canada and centrifuged
at 13200 rpm for 30 min at 48C. The ethanol-soluble
supernatant was then separated from the ethanol-in-
soluble material using a pasteur pipette and both
fractions counted in the gamma counter described
above. Previous work has shown that this technique
results in the precipitation of 59Fe in ferritin and
transferrin, while 59Fe bound to PIH or other chela-
w xtors was not precipitated 19 .
2.8. Statistics
Experimental data were compared using the Stu-
dent’s t-test. Results were considered statistically
significant when P-0.05.
3. Results
3.1. The effect of temperature and metabolic in-
hibitors on chelator-mediated iron release
Initial experiments were designed to examine
whether 59Fe release mediated by the chelators was
temperature-dependent. For the chelators DFO, PIH
and 311, 59Fe release from SK-N-MC NB cells at
 .48C was far less than that found at 378C Fig. 1 . For
example, when DFO or PIH were reincubated with
 .  .  .  . 59Fig. 4. A: the effect of cyclosporin A CsA , quinine Qui , reserpine Res or verapamil Ver , on chelator-mediated Fe release from
59 59 .SK-N-MC neuroblastoma cells. Cells were labelled with Fe-transferrin Fe-Tf; 1.25 mM for 3 h at 378C, washed, and then
 .preincubated for 60 min at 378C with medium containing the inhibitors 20 mM . This medium was subsequently removed and replaced
 .  .  .with medium containing the inhibitor alone 20 mM or the inhibitor 20 mM and the chelator 30 mM which was incubated with the
cells for 60 min at 378C. B: the effect of CsA and Ver on PIH-mediated 59Fe release as a function of incubation time. Cells were labelled
59  .with Fe-Tf, washed, and preincubated with medium containing CsA or Ver as described for A . The cells were then reincubated for 30
 .  .  .  .min, 60 min or 120 min at 378C with either medium alone e—e ; CsA alone 20 mM; ‘- - -‘ ; PIH 30 mM and CsA 20 mM
 .  .  .  .  .^P P P^ ; Ver 20 mM; v – – –v ; or PIH 30 mM and Ver 20 mM %– P –% . C: the effect of CsA and Ver concentration on
59 59  .Fe release by PIH. Cells were labelled with Fe-Tf and washed as described in A and then preincubated with either medium alone or
 . medium containing CsA or Ver 1–40 mM for 1 h at 378C. The cells were then reincubated for 1 h at 378C with either CsA 0–40 mM;
.  .  .  .  .  .  .  .^– – –^ ; CsA 0–40 mM and PIH 30 mM ’—’ ; Ver 0–40 mM; ‘– – –‘ ; or Ver 0–40 mM and PIH 30 mM v —v .
The results are means of duplicate or triplicate determinations in a typical experiment of two experiments performed. The variation
between replicates was generally less than 5%.
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prelabelled cells at 48C, they mobilized only 4–5% of
cellular 59Fe, whereas as 378C, these ligands mobi-
59  .lized 21% and 48% of Fe, respectively Fig. 1 . The
lipophilic PIH analogue, 311, which exhibits high
w xanti-proliferative activity 17,18 , released 10% and
53% of cellular 59Fe when reincubated with prela-
 .belled cells at 48C and 378C, respectively Fig. 1 .
For each chelator the difference in 59Fe release be-
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 .tween 48C and 378C was significant P-0.001 . It is
important to note that at 48C PIH in MEM did not
59  .mobilize any more cellular Fe 3.8% than MEM
 .  .only 4.3% at this temperature Fig. 1 . Hence, the
net 59Fe release by PIH at 48C was zero. In marked
contrast, at 378C 59Fe release by MEM alone was
5.1%, while PIH in MEM mobilized 48.0% of cellu-
lar 59Fe at this temperature, resulting in a net 59Fe
 .release of 42.9% by this ligand Fig. 1 . These exper-
iments suggest that temperature-dependent mecha-
nisms are necessary for chelator-mediated 59Fe mobi-
lization from the cells. Almost identical results were
obtained with the SK-Mel-28 melanoma cell line
 .data not shown .
Examination of 59Fe efflux from SK-N-MC NB
cells as a function of time at 48C and 378C demon-
strated that reincubation at 378C with chelator 311
 . 590.1 mM caused a biphasic release of Fe. This
biphasic release resulted in the efflux of 41% of total
59  .cell Fe after a 3 h reincubation Fig. 2 . In contrast,
when cells were reincubated with 311 at 48C, very
little 59Fe was released for incubation times up to 180
 .min 4.5% after 180 min . When cells were reincu-
bated with medium alone, slightly more 59Fe was
released at 378C than at 48C 5.7% compared to 3.4%
.after 180 min; Fig. 2 . Comparable data were ob-
tained when the experiment was repeated using PIH
 .instead of analogue 311 data not shown .
Further studies examined whether metabolic in-
hibitors prevented 59Fe release mediated by PIH or
 .analogue 311 Fig. 3A . The metabolic inhibitors,
 . sodium azide 30 mM , 2,4-dinitrophenol 50 mM
.  .and 200 mM , rotenone 20 mM and 50 mM and
 .oligomycin 30 mM , all markedly prevented the
release of 59Fe mediated by PIH, whereas they had
either no inhibitory effect sodium azide, rotenone,
.  .oligomycin or far less effect 2,4-dinitrophenol on
59  .Fe release by 311 Fig. 3A . The microtubule in-
hibitor vinblastine was previously shown to inhibit
the efflux of 59Fe from rabbit reticulocytes by PIH
w x19 . In the present study using SK-N-MC NB cells,
 . 59vinblastine 10 mM also reduced PIH-induced Fe
mobilization, whereas 59Fe release by analogue 311
 .was not affected Fig. 3A . At a higher vinblastine
concentration of 50 mM, 59Fe release by 311 was
inhibited to a slightly greater extent than 59Fe release
by PIH, although this was not a consistent finding at
this vinblastine concentration. In some experiments,
vinblastine at 50 mM had no effect on 311-mediated
59Fe release, but always decreased 59Fe release by
PIH. Colchicine is another microtubule distrupting
agent but it had no effect on 59Fe release by PIH or
 .analogue 311 Fig. 3A . None of the agents examined
appreciably affected the total amount of 59Fe present
in the cells compared to the relevant control Fig.
.3B .
The effect of some of the inhibitors on 59Fe release
by other chelators was also investigated. While vin-
 .blastine 50 mM , and especially 2,4-dinitrophenol
 . 59200 mM resulted in a distinct decrease in Fe
released mediated by PIH, these inhibitors had far
less effect on 59Fe release by other PIH analogues
shown to have marked anti-proliferative activity
w x  .17,18 , namely, ligands 206, 309 and 315 Fig. 3C .
 .In similar studies using sodium azide 30 mM and
 .oligomycin 30 mM , comparable results showing a
marked decrease in PIH-mediated 59Fe release but
little effect on 59Fe release by the other chelators
 . 206, 309, 311 and 315 was observed results not
.shown . Under the experimental conditions used,
DFO-mediated 59Fe release was only slightly greater
 .than the control Fig. 3C . Hence, it was difficult to
assess the effect of the inhibitors on 59Fe release
mediated by this latter ligand.
3.2. Effect of inhibitors of P-glycoprotein acti˝ity on
chelator-mediated iron release
 .P-glycoprotein P-gp has been implicated to play
a role in the efflux of a wide variety of lipophilic
w xmolecules from normal and neoplastic cells 27–29 ,
and since the activity of this multi-drug efflux pump
is ATP-dependent, we decided to examine the role of
this molecule in chelator-mediated 59Fe release. Pre-
liminary experiments used 4 widely implemented
inhibitors of P-gp activity, namely cyclosporin A
 .  .  .CsA , quinine Qui , reserpine Res and verapamil
 . w xVer 27–29 . All four inhibitors of P-gp activity
59  .decreased PIH-mediated Fe release Fig. 4A , Ver
and CsA being the most effective drugs. In contrast
to these results, the P-gp inhibitors had little or no
59 effect on Fe release mediated by chelator 311 Fig.
.4A , suggesting that this ligand had a different mech-
anism of release to that found for PIH. The marked
effect of CsA and Ver on PIH-mediated 59Fe efflux
from SK-N-MC NB cells was evident during reincu-
( )D.R. RichardsonrBiochimica et Biophysica Acta 1320 1997 45–57 53
bation periods with the chelators up to 120 min Fig.
.4B . When the cells were incubated with CsA and
Ver alone, these inhibitors had either little or no
effect on 59Fe release compared to when medium
 .alone was used Fig. 4A,B , and both these agents
were effective at inhibiting 59Fe release by PIH at
 .concentrations as low as 1 mM Fig. 4C . A previous
investigation using rabbit reticulocytes showed that
ethanol-soluble 59Fe increased during incubation with
PIH, due to the intracellular accumulation of the
59 w xPIH- Fe complex 19 . In the present study,
ethanol-soluble 59Fe was examined by prelabelling
59  .SK-N-MC cells with Fe-Tf 1.25 mM for 3 h
followed by a reincubation period of 15, 30, or 120
 .min with medium alone control or medium contain-
 .  .ing CsA 30 mM , PIH 30 mM , or these two agents
together. There was little ethanol-soluble 59Fe in
control cells after a 15, 30, and 120 min reincubation,
viz, 7.8%, 7.0% and 4%, respectively. Incubation
with PIH resulted in a slight increase in the amount
59 of ethanol-soluble Fe compared to control cells to
11.7%, 10.5% and 5.8% after 15, 30, and 120 min
.reincubation, respectively . When CsA alone was
incubated with cells it slightly decreased the amount
of ethanol-soluble 59Fe present compared to the con-
trol to 5.1%, 4.9% and 3.3% after 15, 30, and 120
.min . In contrast, incubation of cells with PIH and
CsA resulted in a marked increase in the proportion
of ethanol-soluble 59Fe to a level greater than that
seen with PIH alone to 17.3%, 26.4% and 15.3%
.after a 15, 30, and 120 min reincubation . These
latter data suggested that in the presence of CsA, the
release of the PIH- 59Fe complex was inhibited, re-
sulting in an intracellular accumulation. Similar stud-
ies using Ver also showed comparable results data
.not shown .
3.3. The release of iron from the CH RB30 chinese
hamster o˝ary cell line expressing high le˝els of
P-glycoprotein compared to the control parental line
AuxB1
Additional experiments were designed to examine
if there was any difference in PIH-mediated 59Fe
 .Fig. 5. A: the effect of pyridoxal isonicotinoyl hydrazone PIH
on
59Fe release from the Chinese hamster ovary cell line CHRB30
w xwhich expresses P-glycoprotein at high levels 24 , and the
control parental cell line AuxB1. The cells were incubated for 3 h
59  .at 378C with Fe-transferrin 1.25 mM , washed, and then
reincubated for 1–60 min at 378C with MEM or MEM containing
 .PIH 50 mM . Iron release from control and resistant cells in the
presence of medium alone has been subtracted from the respec-
tive 59Fe release mediated by PIH in each cell type to give a
measure of chelator-mediated release. B: the release of 59Fe from
CHRB30 cells compared to the parental control cell line AuxB1
in the presence of medium only. The experiment was performed
 .as described for A except the cells were reincubated in medium
alone in the absence of PIH. The results are means of duplicate
determinations in a typical experiment of two experiments per-
formed. The variation between replicates was generally less than
5%.
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release between the CHO cell line CHRB30 express-
ing high levels of P-gp and the control cell line Aux
B1. No appreciable difference in the kinetics of 59Fe
release by PIH was found between these two lines
 .Fig. 5A . When similar experiments were performed
using analogue 311, again no difference was ob-
served in the efflux of 59Fe between the resistant and
 .parental CHO cell lines data not shown . However,
in contrast to these results using PIH or 311, in the
CHRB30 cells with high P-gp levels, appreciably
59 more Fe was released into control medium i.e.,
.  .without PIH than the AuxB1 control cells Fig. 5B ,
viz after a 60 min reincubation, 5.9% of total cell
59Fe was released from AuxB1 whereas 16.7% was
released from CHRB30 cells.
4. Discussion
The use of Fe chelators for the treatment of cancer
is a strategy that has been shown to hold promise for
w xsome types of human tumors, including leukemia 4
w xand neuroblastoma 5 . Recently, our studies using
analogues of the tridentate Fe chelator, PIH, have
shown that some of these compounds, particularly
those derived from 2-hydroxy-1-naphthylaldehyde,
are effective anti-proliferative agents that possess
high activity at preventing 59Fe uptake from Tf and
59 w xincreasing Fe release from cells 16–18 . The high
activity of 311 at mobilizing Fe and its potential as a
anti-neoplastic agent has prompted us to investigate
whether this chelator is actively transported out of the
cell. Previous studies have shown that PIH uptake by
rabbit reticulocytes occurred by passive diffusion,
whereas the PIH- 59Fe complex was extruded by an
energy-dependent process that was sensitive to the
w xvinca alkaloids vincristine and vinblastine 19 .
In the present investigation we have examined the
effects of temperature, a number of metabolic in-
hibitors, anti-microtubule agents, and inhibitors of
P-gp activity on 59Fe release from neoplastic cells
mediated by PIH compared to 311. In addition, we
have compared 59Fe release by these chelators in a
CHO cell line expressing high levels of P-gp and a
control line. Interestingly, the release of 59Fe by PIH,
analogue 311 and DFO, were all temperature-depen-
 .dent in both SK-N-MC NB cells Fig. 1 and SK-
Mel-28 melanoma cells. When cells were treated with
four commonly used metabolic inhibitors, namely,
azide, 2,4-dinitrophenol, oligomycin and rotenone,
59Fe release by PIH was markedly inhibited, whereas
these agents had either no effect, or far less effect, on
59  .Fe release mediated by analogue 311 Fig. 3A .
Similar results were also found for a number of other
 .analogues of PIH derived from salicylaldehyde 206
 .or 2-hydroxy-1-naphthylaldehyde 309 and 315 , all
of which were not appreciably affected by a range of
 .metabolic inhibitors Fig. 3C . These results were
surprizing, since they suggest that while the efflux of
the PIH-59Fe complex requires energy, the release of
its structurally related analogues appears to be en-
ergy-independent. A previous investigation by Huang
w xand Ponka 19 using reticulocytes demonstrated that
the uptake of 14C-PIH into the cell was energy-inde-
pendent and via passive diffusion, while the release
of 14C-labelled PIH was markedly reduced by 2,4-di-
nitrophenol. Further, it was shown that the inhibited
transport of PIH resulted in an accumulation of the
14 w xC-labelled molecule in the reticulocyte 19 . These
latter experiments suggested that energy was neces-
sary for PIH release, and substantiate the results of
the present study using neoplastic cells.
In the current work, cells have been prelabelled
with 59Fe and then reincubated with chelators in the
presence and absence of metabolic inhibitors Fig.
.3A–C . Critically, it could be suggested that the
decrease in PIH-59Fe mobilization seen in the pres-
 .ence of these agents Fig. 3A could be due to the
inhibitors altering the total amount of 59Fe, or alterna-
tively, the cellular distribution of 59Fe. However,
these agents had no effect on the total amount of 59Fe
 .in the cells compared to the control Fig. 3B . In
addition, if these inhibitors were altering the distribu-
tion of 59Fe to prevent PIH-mediated 59Fe release, it
would not explain why 59Fe release by 311 was not
 .affected to the same extent as PIH Fig. 3A , since
both PIH and 311 mobilize 59Fe from the same Fe
w xpools 18 . Hence, these results suggest that the in-
hibitors were not altering the total amount of 59Fe in
the cells or the intracellular 59Fe distribution.
Generally, energy-independent transport has been
described to occur by either simple diffusion or pas-
sive transport involving either channel- or carrier-
w xmediated diffusion 30 . With this in mind, it should
be noted that the PIH-analogues are far more
w xlipophilic than PIH 15,17 , and this may be a crucial
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factor in determining their route of release. It can be
suggested that the high lipophilicity of the PIH ana-
logues facilitates rapid diffusion and allows them to
bypass the energy-dependent transport route. It is also
known that PIH becomes more hydrophilic upon
w xbinding Fe 15 , which probably accounts for the
slight intracellular accumulation seen in the present
study using SK-N-MC NB cells and in previous work
w xusing rabbit reticulocytes 19 . Perhaps the cellular
accumulation of the PIH-59Fe complex aids it in
obtaining access to an energy-requiring transporter.
Similarly, previous investigations studying the active
transport of steroids from cells indicated that the
more lipophilic steroids such as progesterone ap-
peared to pass through membranes largely by passive
diffusion, whereas the hydrophilic steroid cortisol
was transported by an ATP-dependent mechanism
w x31 .
Since 59Fe release by 311 was seemingly energy-
independent, it was surprizing that chilling the cells
59  .to 48C inhibited Fe mobilization Fig. 1 . This
marked decrease in 311-mediated 59Fe release may
be explained by changes in the fluidity of the cell
membrane that is known to occur upon reducing the
w xtemperature from 378C 32 . This change could possi-
bly effect diffusion of molecules, especially if passive
transport was involved, where the appropriate confor-
mation of channels or carriers may be affected by
temperature. Another potential explanation is also
possible, at 378C the 59Fe pools within cells may be
in a different state than when the cells are chilled to
48C. For instance, it may be that the chelators access
a metabolic pool of 59Fe that is only chelatable at
378C, at 48C this pool may not be in a state that can
be bound by the ligands. It can also be proposed that
the lack of 59Fe mobilization at 48C by the chelators
could be due to the inhibited uptake of the ligands by
w xthe cells. However, Huang and Ponka 19 have
shown that the uptake of 14C-labelled PIH into cells
is via passive diffusion. In the present investigation,
the uptake of 14C-ligands could not be examined due
to the current lack of commercially available precur-
sors of the chelators. Further studies are obviously
necessary to determine the mechanism responsible
for temperature-dependent Fe chelation by these lig-
ands. However, it can be suggested that the inhibition
of Fe chelation at 48C appears to be via a different
mechanism to that found for the metabolic inhibitors,
since energy depletion resulted in a distinct decrease
59  .in Fe release by PIH only Fig. 3A , whereas
chilling the cells to 48C markedly prevented 59Fe
 .mobilization by both PIH and 311 Fig. 1 .
In contrast to 311 and the other PIH analogues,
PIH was transported by a process that was markedly
depressed upon incubating the cells with metabolic
 .inhibitors Fig. 3A,C . Considering the possible
 .transport mechanism s involved, it has been demon-
strated that P-gp is an energy-dependent efflux pump
that can transport a very diverse variety of organic
w xcompounds 27–29 . Further, this transporter is found
in a wide variety of normal and neoplastic cell types
 .including NB cells that have not been exposed to
w xcytotoxic agents 27–29 . In preliminary studies we
examined the effect of 4 widely used inhibitors of
P-gp activity on 59Fe release by PIH and 311. All 4
of these compounds, namely CsA, Qui, Res, and Ver,
effectively decreased 59Fe mobilization by PIH but
had either little or no effect on 59Fe release mediated
 .by analogue 311 Fig. 4A . Furthermore, when PIH
was incubated in the presence of CsA or Ver, the
amount of ethanol-soluble 59Fe increased within the
cell to a greater extent than that seen with PIH alone,
suggesting accumulation of the 59Fe chelate due to
inhibited transport. While these inhibitors are exten-
w xsively used to inhibit P-gp transport activity 27–29 ,
it should be noted they are not specific, and can
w xaffect many other cellular processes 27 . In fact, the
detergents Tween 80 and Lubrol wx can mimic the
w xeffect of Ver on drug transport 27 , which indicates
the activity of this drug may result from its ability to
w xgenerally perturb the cell membrane 27 . In this
light, when experiments were performed using a well
characterized multi-drug resistant CHO cell line
 R . w xCH B30 with high P-gp expression 24 , these cells
were no more efficient at releasing the PIH-59Fe
complex than the control parental CHO cells AuxB1;
. 59Fig. 5A . The role of P-gp in PIH-mediated Fe
release could also be questioned from our experi-
 .ments showing that high concentrations 100 mM of
the P-gp substrate, colchicine, had no appreciable
59  .effect on Fe release by PIH Fig. 3A . These latter
observations and particularly the experiments using
the control and P-gp amplified cell lines suggest that
P-gp is not involved in release of the PIH-59Fe
complex, and clearly contradict the results using the
P-gp inhibitors. These two seemingly conflicting sets
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of results could be rationalized by suggesting that
another energy-dependent transport mechanism may
be responsible for PIH-mediated 59Fe release. It is
well known that P-glycoprotein belongs to a family
of related transporters that contain ATP-binding cas-
settes also known as ABC proteins or traffic AT-
w x.Pases; 28,29 , and the drug efflux activity of some
of these proteins can be affected by traditional in-
w xhibitors of P-gp 33 .
Despite there being no appreciable difference in
the efflux of PIH between the control and P-gp
amplified cell lines, it was intriguing that the CHRB30
cell line with high P-gp levels, released appreciably
59  .more Fe into control medium i.e., without PIH
 .than the parental control cells, AuxB1 Fig. 5B .
These results could suggest that P-gp may play some
role in 59Fe release, and further studies are necessary
to examine this intriguing observation further. At
present, very little information is known concerning
the mechanism of Fe efflux from cells, especially
from hepatocytes and macrophages, where the
physiological role of Fe release has long been recog-
 w x.nized for review, see 34 . Since P-gp and certain
members of this transmembrane pump family have
w xbeen shown to transport a wide range of drugs 27–29
w xand natural substrates 35–37 , it is not unreasonable
to suggest that this protein may be capable of trans-
porting Fe bound to intracellular ligands, and studies
have been initiated to examine this further.
The fact that some chelators such as PIH can be
transported from cells by energy-dependent mecha-
nisms may actually facilitate their anti-proliferative
action by resulting in greater intracellular Fe release.
Based on the structure of agents known to be trans-
ported by P-gp, it may be possible to design chelators
that can be transported by this protein. Hence, the
appearance of chemotherapy-resistant tumors due to
the amplification of P-gp could be potentially treated
with these specially designed ligands that can enter
the cell, bind Fe from critically sensitive compart-
ments, and then be pumped out by P-gp. On the other
hand, the efficacy of chelators such as 311 that are
rapidly transported across the membrane by simple
diffusion or passive transport may not be affected by
the emergence of cells with increased transporter
activity, and will remain highly effective anti-pro-
liferative agents. Thus, additional work examining
the membrane transport of Fe chelators may be useful
in designing treatment regimes that enhance their
anti-proliferative effects.
In conclusion, this study has demonstrated that the
mechanism involved in the release of PIH from SK-
N-MC NB cells is energy-dependent. In contrast, the
closely related PIH analogue, 311, appears to be
released from cells by an energy-independent process
that is consistent with simple diffusion or passive
transport.
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